Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors
August 07 2013 - 8:00AM
Business Wire
Oral inhibitor of phosphorylated-p68 RNA
helicase marks Rexahn’s third oncology compound in clinical
development
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Oct 2024 to Nov 2024
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Nov 2023 to Nov 2024